All News
Filter News
Found 3,381 articles
-
60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in Boston
10/19/2023
60 Degrees Pharmaceuticals, Inc. will present a poster titled, “Long-term safety of the tafenoquine antimalarial chemoprophylaxis regimen, a 12-month, randomized double-blind placebo-controlled trial” at the International Lyme & Associated Diseases Society annual conference in Boston on October 21, 2023.
-
Press Release: Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio
10/19/2023
Sanofi has delivered the first medicines from its Global Health Unit’s not-for-profit Impact brand portfolio to the Republic of Djibouti.
-
AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease
10/18/2023
AN2 Therapeutics, Inc. today announced that it has received an exclusive license from the University of Georgia Research Foundation to advance the development of a boron-containing small molecule for Chagas disease.
-
Ocean Biomedical (NASDAQ: OCEA) Announces Enrollment of Patients for Phase 1b Study for Chronic Hepatitis B Treatment in 50-50 Joint Venture with Virion Therapeutics
10/17/2023
Ocean Biomedical, Inc. (NASDAQ:OCEA) today announced that its joint venture partner, Virion Therapeutics, LLC, is now enrolling patients in its Phase 1b study for a first-in-class treatment of chronic Hepatitis B (Clinicaltrials.gov #NCT06070051) in Hong Kong and New Zealand, with additional sites in the United States to become active later this year.
-
Ocean Biomedical and Virion Therapeutics Form Joint Venture Supporting Multi-National, First-In-Humans Clinical Chronic Hepatitis B Study: Now Enrolling, With Goal of a Functional Cure for a Disease Affecting 300+ Million Patients Worldwide
10/12/2023
Ocean Biomedical, Inc. and Virion Therapeutics, LLC announced they have entered into a joint venture to accelerate and expand Virion’s clinical-stage program and pipeline, with the goal of finding cures for patients with cancer and chronic infectious diseases.
-
60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases
10/12/2023
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced that its subsidiary, 60P Australia Pty Ltd, will not re-submit its investigational new drug application (“IND”) for ACLR8-LR, a Phase IIB study of tafenoquine compared to placebo in patients with mild to moderate COVID-19 disease and low risk of disease progression.
-
Virion Therapeutics and Ocean Biomedical form joint venture supporting multi-national, first-in-humans clinical chronic hepatitis B study
10/12/2023
Virion Therapeutics, LLC, and Ocean Biomedical, Inc. today announced they have entered into a joint venture to accelerate and expand Virion's clinical-stage program and pipeline, with the goal of finding cures for patients with cancer and chronic infectious diseases.
-
Gates Foundation Celebrates 20 Years of "Grand Challenges" With New Investments and a Call to Make R&D Breakthroughs Available More Quickly and Equitably
10/10/2023
A slate of new initiatives to support locally led innovation was announced in Dakar by the Bill & Melinda Gates Foundation and its partners at the Grand Challenges Annual Meeting.
-
BIOVECTRA Signs Service Agreement With Acuitas Therapeutics for Unique Lipid Nanoparticle (LNP) Delivery System Used in Manufacturing mRNA-Based Therapies
10/5/2023
BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service agreement under which BIOVECTRA will accept, on a non-exclusive basis, Acuitas’ best-in-class LNP technology platform for manufacturing mRNA-based therapeutics.
-
Ocean Biomedical Announces Loan Commitment from Largest Stockholder; Up to $10 Million
10/4/2023
Ocean Biomedical, Inc. (NASDAQ: OCEA ) announced today that it has entered into a non-binding term sheet with its largest stockholder, Poseidon Bio, LLC, majority owned by Dr. Chirinjeev Kathuria, for a proposed debt facility consisting of convertible promissory notes with a principal amount of up to $10 million.
-
Updated: Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with Polar Multi-Strategy Master Fund
10/4/2023
Ocean Biomedical, Inc. announces that the company and Polar Multi-Strategy Master Fund entered into a Side Letter related to the Forward Purchase Agreement entered into in February 2023.
-
Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca’s Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers
10/3/2023
Ocean Biomedical, Inc. announced that its cancer-targeting immunotherapy antibody candidate has demonstrated effective tumor reduction against an aggressive subset of Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor mutations.
-
Takeda’s Dengue Vaccine Recommended by World Health Organization Advisory Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to 16 Years
10/3/2023
Takeda announced that the World Health Organization’s Strategic Advisory Group of Experts on Immunization shared recommendations for use of QDENGA®▼.
-
Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with a Key Financing Partner
10/3/2023
Ocean Biomedical, Inc. announced that the company and Polar Multi-Strategy Master Fund, a significant long-time financing partner of Ocean Biomedical, agreed to amend the agreement between the parties related to the Forward Shares Purchase Agreement entered into in February 2023.
-
The COVID-19 pandemic highlighted a need for local production of vaccines. Now, German pharma company BioNTech has said it will start manufacturing vaccines in Africa.
-
AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria
9/26/2023
AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria.
-
Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross
9/21/2023
Atreca, Inc. announced that, as part of its ongoing efforts to lower operating expenses, the Company has entered into an agreement to terminate its lease agreement pertaining to the Company's headquarters in San Carlos, CA, which represented approximately $13 million of annual expenditures.
-
Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
9/20/2023
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first participant has been dosed in a Phase 1 trial evaluating the safety, reactogenicity and immunogenicity of VIR-1388, an investigational novel T cell vaccine for the prevention of human immunodeficiency virus (HIV).
-
Danaher to Provide Cepheid's Tuberculosis Test to the Global Fund at Cost
9/19/2023
Danaher Corporation announced it will provide Cepheid's Xpert® MTB/RIF Ultra diagnostic test cartridges for tuberculosis at Cepheid's cost of $7.97 each to the Global Fund to Fight AIDS, TB and Malaria and to less-developed countries eligible for Cepheid's Global Access Program1 to support greater access to high-quality TB testing.
-
60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements
9/18/2023
60 Degrees Pharmaceuticals, Inc. (“60P”) (NASDAQ: SXTP), specialists in developing and marketing medicines for infectious diseases, today announced that 60P Australia Pty Ltd, a majority-owned subsidiary of 60P, has withdrawn its investigational new drug (IND) application for ACLR8-LR, a Phase IIB study of the use of tafenoquine in treating COVID-19, and intends to submit a new IND in the fourth quarter.